SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 26, 2004
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
|
Oregon |
|
0-22613 |
|
93-0797222 |
|
(State
or other jurisdiction of |
|
(Commission File Number) |
|
(IRS
Employer |
One S.W. Columbia, Suite 1105
Portland, OR 97258
(Address of principal executive offices)
(503) 227-0554
Registrant’s telephone number, including area code
Item 5. Other Events and Regulation FD Disclosure.
The information set forth below pursuant to Item 12 shall also be deemed filed pursuant to Item 5.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
|
Exhibit Number |
|
Description |
|
99.1 |
|
Press Release dated January 26, 2004 announced the presentation of test study results demonstrating the therapeutic manipulation of the immune system using AVI’s NeuGene® antisense compounds at the Midwinter Conference of Immunologists. |
Item 12. Results of Operations and Financial Condition.
Company issued a press release on January 26, 2004, before the opening of trading in its Common Stock on the Nasdaq National Market System. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
The Press Release dated January 26, 2004 announced the presentation of test study results demonstrating the therapeutic manipulation of the immune system using AVI’s NeuGene® antisense compounds at the Midwinter Conference of Immunologists.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on January 27, 2004.
|
|
AVI BioPharma, Inc. |
||
|
|
|
||
|
|
By: |
/s/ ALAN P.TIMMINS |
|
|
|
|
Alan P. Timmins |
|
2